T M Drake1,2, A E Ward3. 1. Academic Unit of Surgical Oncology, The Medical School, University of Sheffield, Sheffield, S10 2RX, UK. TMDrake1@sheffield.ac.uk. 2. Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, LS2 9JT, UK. TMDrake1@sheffield.ac.uk. 3. Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, S10 2JF, UK.
Abstract
BACKGROUND: Prolonged ileus is a common complication following gastrointestinal surgery, with an incidence of up to 40 %. Investigations examining pharmacological treatment of ileus have proved largely disappointing; however, recently, several compounds have been shown to have benefited when used as prophylaxis to prevent ileus. OBJECTIVE: This review aimed to evaluate the safety and efficacy of compounds which have been recently developed or repurposed to reduce bowel recovery time, thereby preventing ileus. DATA SOURCES: Data were taken from a systematic review of the MEDLINE, EMBASE and Cochrane Library Databases, in addition to manual searching of reference lists up to April 2015. No limits were applied. STUDY SELECTION: Only randomized trials were eligible for inclusion. INTERVENTIONS: Opioid receptor antagonists, ghrelin receptor agonists and serotonin receptor agonists used for the prevention of postoperative ileus in gastrointestinal surgery. MAIN OUTCOME MEASURES: Outcomes of time to first defecation, first flatus and composite bowel recovery endpoints (GI2 and GI3) were used to determine efficacy. Pooled treatment effects were presented as the standard mean difference or as hazard ratios alongside the corresponding 95 % confidence intervals. Risk of bias was assessed using the Cochrane risk of bias framework. RESULTS: A total of 17 studies were included in the final analysis. The μ-opioid receptor antagonist alvimopan and serotonin receptor agonists appeared to significantly shorten the duration of ileus. The use of Ghrelin receptor agonists did not appear to have any effect in five trials. No publication bias was detected. LIMITATIONS: Most of the trials were poorly reported and of mixed quality. Future studies must focus on the development of a set of core outcomes. CONCLUSIONS: There is evidence to make a strong recommendation for the use of alvimopan in major gastrointestinal surgery to reduce postoperative ileus. Further randomized trials are required to establish whether serotonin receptor agonists are of use. Identifying a low-cost compound to promote bowel recovery following surgery could reduce complications and shorten duration of hospital admissions.
BACKGROUND: Prolonged ileus is a common complication following gastrointestinal surgery, with an incidence of up to 40 %. Investigations examining pharmacological treatment of ileus have proved largely disappointing; however, recently, several compounds have been shown to have benefited when used as prophylaxis to prevent ileus. OBJECTIVE: This review aimed to evaluate the safety and efficacy of compounds which have been recently developed or repurposed to reduce bowel recovery time, thereby preventing ileus. DATA SOURCES: Data were taken from a systematic review of the MEDLINE, EMBASE and Cochrane Library Databases, in addition to manual searching of reference lists up to April 2015. No limits were applied. STUDY SELECTION: Only randomized trials were eligible for inclusion. INTERVENTIONS: Opioid receptor antagonists, ghrelin receptor agonists and serotonin receptor agonists used for the prevention of postoperative ileus in gastrointestinal surgery. MAIN OUTCOME MEASURES: Outcomes of time to first defecation, first flatus and composite bowel recovery endpoints (GI2 and GI3) were used to determine efficacy. Pooled treatment effects were presented as the standard mean difference or as hazard ratios alongside the corresponding 95 % confidence intervals. Risk of bias was assessed using the Cochrane risk of bias framework. RESULTS: A total of 17 studies were included in the final analysis. The μ-opioid receptor antagonist alvimopan and serotonin receptor agonists appeared to significantly shorten the duration of ileus. The use of Ghrelin receptor agonists did not appear to have any effect in five trials. No publication bias was detected. LIMITATIONS: Most of the trials were poorly reported and of mixed quality. Future studies must focus on the development of a set of core outcomes. CONCLUSIONS: There is evidence to make a strong recommendation for the use of alvimopan in major gastrointestinal surgery to reduce postoperative ileus. Further randomized trials are required to establish whether serotonin receptor agonists are of use. Identifying a low-cost compound to promote bowel recovery following surgery could reduce complications and shorten duration of hospital admissions.
Authors: F Levin; T Edholm; P T Schmidt; P Grybäck; H Jacobsson; M Degerblad; C Höybye; J J Holst; J F Rehfeld; P M Hellström; E Näslund Journal: J Clin Endocrinol Metab Date: 2006-06-13 Impact factor: 5.958
Authors: E R Viscusi; S Goldstein; T Witkowski; A Andonakakis; R Jan; K Gabriel; W Du; L Techner; B Wallin Journal: Surg Endosc Date: 2005-12-07 Impact factor: 4.584
Authors: B Y De Winter; G E Boeckxstaens; J G De Man; T G Moreels; J A Schuurkes; T L Peeters; A G Herman; P A Pelckmans Journal: Gut Date: 1999-11 Impact factor: 23.059
Authors: Kirk Ludwig; Warren E Enker; Conor P Delaney; Bruce G Wolff; Wei Du; John G Fort; Maryann Cherubini; James Cucinotta; Lee Techner Journal: Arch Surg Date: 2008-11
Authors: Alessandro Montedori; Maria Isabella Bonacini; Giovanni Casazza; Maria Laura Luchetta; Piergiorgio Duca; Francesco Cozzolino; Iosief Abraha Journal: Trials Date: 2011-02-28 Impact factor: 2.279
Authors: Mohsen Alhashemi; Julio F Fiore; Nadia Safa; Mohammed Al Mahroos; Juan Mata; Nicolò Pecorelli; Gabriele Baldini; Nandini Dendukuri; Barry L Stein; A Sender Liberman; Patrick Charlebois; Franco Carli; Liane S Feldman Journal: Surg Endosc Date: 2018-10-17 Impact factor: 4.584
Authors: R Nascimbeni; A Amato; R Cirocchi; A Serventi; A Laghi; M Bellini; G Tellan; M Zago; C Scarpignato; G A Binda Journal: Tech Coloproctol Date: 2020-11-05 Impact factor: 3.781